Patents by Inventor Dale A. Schenk
Dale A. Schenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050163788Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: July 28, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050158304Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: July 12, 2004Publication date: July 21, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Publication number: 20050142132Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: February 14, 2005Publication date: June 30, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Publication number: 20050123544Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: November 24, 2004Publication date: June 9, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Publication number: 20050069968Abstract: This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-? peptide (x-?41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A?(x-?41) and tau. Low levels of A?(x-?41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A?(x-?41) and low levels of tau are a negative indication of Alzheimer's disease.Type: ApplicationFiled: October 12, 2004Publication date: March 31, 2005Applicants: Athena Neurosciences, Inc., Elan Pharmaceuticals, Inc.Inventors: Peter Seubert, Carmen Vigo-Pelfrey, Dale Schenk, Robin Barbour
-
Publication number: 20050059591Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: April 12, 2004Publication date: March 17, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Nicki Vasquez, Theodore Yednock
-
Publication number: 20050059802Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: February 11, 2004Publication date: March 17, 2005Inventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Publication number: 20050053614Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: July 1, 2004Publication date: March 10, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050048049Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: March 3, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050037013Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: August 9, 2004Publication date: February 17, 2005Applicants: Elan Pharmaceuticals, Inc., The Regents of the University of CaliforniaInventors: Dale Schenk, Eliezer Masliah
-
Publication number: 20050037026Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: February 17, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050031629Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: March 31, 2004Publication date: February 10, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050019330Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: January 27, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050019328Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: April 12, 2004Publication date: January 27, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050019343Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: January 27, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050013815Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: January 20, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050009150Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.Type: ApplicationFiled: August 30, 2002Publication date: January 13, 2005Applicant: Elan Pharmaceuticals, Inc.Inventors: Guriq Basi, Jose Saldanha, Ted Yednock, Dale Schenk
-
Patent number: 6610493Abstract: This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x≧41) alone or in combination with A&bgr;(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x≦40) and A&bgr;(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.Type: GrantFiled: June 18, 1996Date of Patent: August 26, 2003Assignees: Brigham and Women's Hospital, Athena Neurosciences, Inc.Inventors: Martin Citron, Dennis J. Selkoe, Peter A. Seubert, Dale Schenk
-
Patent number: 5422244Abstract: The present invention is related generally to methods and compositions for identifying and quantitating particular .alpha.1-antichymotrypsin species in a biological sample. More particularly, the present invention is related to methods and compositions for detecting and measuring a brain .alpha.1-antichymotrypsin species that is produced in brain tissue of individuals having a neuropathological condition and which is detectable in accessible biological samples. The invention provides detection assays, such as sandwich binding assays, for detecting and quantitating brain .alpha.1-antichymotrypsin in a biological sample, such as blood, urine, cerebrospinal fluid, or tissue. These detection assays are useful for detecting and diagnosing neuropathological diseases and for identifying cells of a human central nervous system lineage, and for other medical applications. The invention also provides binding components, such as antibodies that bind to brain .alpha.Type: GrantFiled: May 5, 1992Date of Patent: June 6, 1995Assignee: Athena Neurosciences, Inc.Inventors: Kelly Johnson-Wood, Dale Schenk